| iSCIB1+ MHRA CTA Approval for Ph3 trial | 19-Aug-2026 | 07:00 | RNS |
| Holding(s) in Company | 06-Aug-2026 | 13:00 | RNS |
| Holding(s) in Company | 31-Jul-2026 | 17:32 | RNS |
| Extension of Option Exercise Period | 31-Jul-2026 | 07:00 | RNS |
| Holding(s) in Company | 28-Jul-2026 | 15:40 | RNS |
| Result of Retail Offer and Total Voting Rights | 27-Jul-2026 | 07:00 | RNS |
| Correction: Merger and Financing | 24-Jul-2026 | 07:30 | RNS |
| Oversubscribed UK Placing | 23-Jul-2026 | 16:30 | RNS |
| Merger and Financing | 23-Jul-2026 | 08:05 | RNS |
| Launch of Retail Offer | 23-Jul-2026 | 08:04 | RNS |
| Proposed UK Placing | 23-Jul-2026 | 08:04 | RNS |
| Scancell: Response to Press Speculation | 26-Jun-2026 | 14:13 | RNS |
| FDA Fast Track Designation for iSCIB1+ | 28-Apr-2026 | 07:00 | RNS |
| Scancell announces CFO transition | 02-Apr-2026 | 07:00 | RNS |
| Half-year Financial Report | 29-Jan-2026 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 9.70p |
| Change Today | 0.20p |
| % Change | 2.11 % |
| 52 Week High | 26.25 |
| 52 Week Low | 8.54 |
| Volume | 9,389,334 |
| Shares Issued | 1,212.23m |
| Market Cap | £117.59m |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 13:09 | 2,962,000 @ 9.50p |
| 17:08 | 25,000 @ 9.70p |
| 16:29 | 81,632 @ 9.80p |
| 16:28 | 102,040 @ 9.80p |
| 16:27 | 219,387 @ 9.80p |
| CFO | Sath Nirmalananthan |
| CEO | Phil L'Huillier |
You are here: research